The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...

The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...